| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1371564 | Bioorganic & Medicinal Chemistry Letters | 2010 | 4 Pages |
Abstract
A series of potent, benzimidazole-based SCD inhibitors which demonstrate selectivity for the hSCD1 enzyme over the hSCD5 isoform are described. The compounds possess suitable cellular activity and pharmacokinetic properties which render them capable of inhibiting liver SCD activity in a mouse pharmacodynamic assay. These 2-aryl benzimidazoles may serve as valuable tools for studying selective hSCD1-inhibition.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
David A. Powell, Yeeman Ramtohul, Marie-Eve Lebrun, Renata Oballa, Sathesh Bhat, Jean-Pierre Falgueyret, Sebastien Guiral, Zheng Huang, Kathryn Skorey, Paul Tawa, Lei Zhang,